择期腹主动脉瘤修复术后5年生存预测模型的外部验证
本研究在单中心1038例择期修复无症状且直径<6.5 cm腹主动脉瘤患者中,外部验证既往VSGNE 5年生存预测模型。
要点
- VSGNE模型在外部人群中区分度与校准度良好,可预测5年生存。
- 模型基于年龄、冠心病、COPD、肾功能及抗血小板/他汀使用。
核心结论
- 评估年龄及心、肺、肾疾病水平可跨人群准确预测直径<6.5 cm腹主动脉瘤修复术后5年生存。
- 该风险预测模型是评估择期腹主动脉瘤修复总体生存获益的valid方法。
研究设计与样本
- 单中心回顾性外部验证研究,验证组为2002至2011年择期修复无症状且直径<6.5 cm腹主动脉瘤的1038例患者(59%为腔内修复)。
- 推导组为既往发表的VSGNE模型队列,共2367例患者(70%为腔内修复)。
- 评估区分度(一致性指数)、校准度(校准斜率和大范围校准)及拟合优度(得分检验)。
主要发现
- 验证组较推导组稍年长(74 vs 72岁;P<.01),男性比例更高(76% vs 68%;P<.01)。
- 推导组晚期心脏病、COPD比例及基线肌酐浓度更高(1.2 vs 1.1 mg/dL;P<.01)。
- 验证组与推导组5年生存率相似(75% vs 77%;P=.33)。
- 验证组一致性指数与推导组均为0.659(95%CI 0.63-0.69)。
- 大范围校准值为1.02(P=.62),校准斜率为0.84(95%CI 0.71-0.97),得分检验P=.57。
关键数值与推荐
- 推导组中与生存相关的主要因素为年龄、冠心病、COPD、肾功能及抗血小板和他汀类药物使用。
- 一致性指数0.659(95%CI 0.63-0.69)。
- 大范围校准值1.02(P=.62),校准斜率0.84(95%CI 0.71-0.97),得分检验P=.57。
临床怎么用
- 可用于评估直径<6.5 cm无症状腹主动脉瘤患者择期修复后的5年生存风险,辅助患者选择。
- 结合年龄、冠心病、COPD、肾功能及用药情况综合判断总体生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The benefit of prophylactic repair of abdominal aortic aneurysms (AAAs) is based on the risk of rupture exceeding the risk of death from other comorbidities. The purpose of this study was to validate a 5-year survival prediction model for patients undergoing elective repair of asymptomatic AAA <6.5 cm to assist in optimal selection of patients. METHODS: All patients undergoing elective repair for asymptomatic AAA <6.5 cm (open or endovascular) from 2002 to 2011 were identified from a single institutional database (validation group). We assessed the ability of a prior published Vascular Study Group of New England (VSGNE) model (derivation group) to predict survival in our cohort. The model was assessed for discrimination (concordance index), calibration (calibration slope and calibration in the large), and goodness of fit (score test). RESULTS: The VSGNE derivation group consisted of 2367 patients (70% endovascular). Major factors associated with survival in the derivation group were age, coronary disease, chronic obstructive pulmonary disease, renal function, and antiplatelet and statin medication use. Our validation group consisted of 1038 patients (59% endovascular). The validation group was slightly older (74 vs 72 years; P < .01) and had a higher proportion of men (76% vs 68%; P < .01). In addition, the derivation group had higher rates of advanced cardiac disease, chronic obstructive pulmonary disease, and baseline creatinine concentration (1.2 vs 1.1 mg/dL; P < .01). Despite slight differences in preoperative patient factors, 5-year survival was similar between validation and derivation groups (75% vs 77%; P = .33). The concordance index of the validation group was identical between derivation and validation groups at 0.659 (95% confidence interval, 0.63-0.69). Our validation calibration in the large value was 1.02 (P = .62, closer to 1 indicating better calibration), calibration slope of 0.84 (95% confidence interval, 0.71-0.97), and score test of P = .57 (>.05 indicating goodness of fit). CONCLUSIONS: Across different populations of patients, assessment of age and level of cardiac, pulmonary, and renal disease can accurately predict 5-year survival in patients with AAA <6.5 cm undergoing repair. This risk prediction model is a valid method to assess mortality risk in determining potential overall survival benefit from elective AAA repair.
引用
- DeMartino RR, Huang Y, Mandrekar J, et al. External validation of a 5-year survival prediction model after elective abdominal aortic aneurysm repair. J Vasc Surg. 2017. PMID: 28807385. doi:10.1016/j.jvs.2017.05.104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。